Article

Comment on ‘Management of Cardiac Sarcoidosis in 2020’

Disclosure: The authors have no conflicts of interest to declare.

Received:

Accepted:

Published online:

Citation:Arrhythmia & Electrophysiology Review 2021;10(2):125.

Correspondence: Socrates Korovesis, Department of Cardiology, Hygeia Hospital, 15123 Athens, Greece. E: skorovessis64@gmail.com

Open access:

This work is open access under the CC-BY-NC 4.0 License which allows users to copy, redistribute and make derivative works for non-commercial purposes, provided the original work is cited correctly.

We read with great interest the profound and instructive review by Gilotra et al. on cardiac sarcoidosis.1 However, we were surprised to see no comment on the raised possibility that steroids might precipitate electrical instability.2 Ventricular tachyarrhythmias and electric storm have been reported to frequently occur in the first 12 months after initiation of corticosteroid therapy.3 This is an issue of clinical importance and it would have been useful to include this in the review along with a commentary from the authors.

References

  1. Gilotra N, Okada D, Sharma A, Chrispin J. Management of cardiac sarcoidosis in 2020. Arryth Electrophysiol Rev 2020;9:182–8.
    Crossref | PubMed
  2. Okada DR, Smith J, Derakhshan A, et al. Ventricular arrhythmias in cardiac sarcoidosis. Circulation 2018;138:1253–64.
    Crossref | PubMed
  3. Segawa M, Fukuda K, Nakano M, et al. Time course and factors correlating with ventricular tachyarrhythmias after introduction of steroid therapy in cardiac sarcoidosis. Circ Arrhythm Electrophysiol 2016;9:e003353.
    Crossref | PubMed